BR0014440A - Formulações de liberação controlada oral - Google Patents

Formulações de liberação controlada oral

Info

Publication number
BR0014440A
BR0014440A BR0014440-1A BR0014440A BR0014440A BR 0014440 A BR0014440 A BR 0014440A BR 0014440 A BR0014440 A BR 0014440A BR 0014440 A BR0014440 A BR 0014440A
Authority
BR
Brazil
Prior art keywords
controlled release
release formulations
oral controlled
oral
rivastigmine
Prior art date
Application number
BR0014440-1A
Other languages
English (en)
Inventor
Rajen Shah
Satish Chandra Khanna
Oskar Kalb
Joerg Ogorka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0014440(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0014440A publication Critical patent/BR0014440A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: "FORMULAçõES DE LIBERAçãO CONTROLADA ORAL". A presente invenção refere-se a composição farmacêutica capaz de liberação de uma dosagem terapeuticamente eficaz do agente ativo, por exemplo, rivastigmina, em uma maneira controlada em tempo.
BR0014440-1A 1999-09-29 2000-09-27 Formulações de liberação controlada oral BR0014440A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923045.0A GB9923045D0 (en) 1999-09-29 1999-09-29 New oral formulations
PCT/EP2000/009455 WO2001022944A1 (en) 1999-09-29 2000-09-27 Oral controlled release formulations

Publications (1)

Publication Number Publication Date
BR0014440A true BR0014440A (pt) 2002-06-18

Family

ID=10861819

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014440-1A BR0014440A (pt) 1999-09-29 2000-09-27 Formulações de liberação controlada oral

Country Status (31)

Country Link
US (2) US20060246101A1 (pt)
EP (1) EP1216032B1 (pt)
JP (1) JP2003510268A (pt)
KR (2) KR100661441B1 (pt)
CN (1) CN1213737C (pt)
AR (1) AR025792A1 (pt)
AT (1) ATE384517T1 (pt)
AU (1) AU769646B2 (pt)
BR (1) BR0014440A (pt)
CA (1) CA2379595A1 (pt)
CO (1) CO5210867A1 (pt)
CY (1) CY1107923T1 (pt)
CZ (1) CZ301455B6 (pt)
DE (1) DE60037897T2 (pt)
DK (1) DK1216032T3 (pt)
EC (1) ECSP003685A (pt)
ES (1) ES2299438T3 (pt)
GB (1) GB9923045D0 (pt)
HU (1) HUP0202744A3 (pt)
IL (2) IL148908A0 (pt)
MY (1) MY128759A (pt)
NO (1) NO331480B1 (pt)
NZ (1) NZ517335A (pt)
PE (1) PE20010568A1 (pt)
PL (1) PL200822B1 (pt)
PT (1) PT1216032E (pt)
RU (1) RU2281758C2 (pt)
SK (1) SK286651B6 (pt)
TR (1) TR200200683T2 (pt)
WO (1) WO2001022944A1 (pt)
ZA (1) ZA200202369B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
CN101849921A (zh) 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂
JP4971159B2 (ja) 2004-08-13 2012-07-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
BR112013006381B1 (pt) 2010-09-20 2024-02-15 Spi Pharma Inc Composição que compreende um material de núcleo tendo um valor de sabor e um revestimento polimérico e formulação farmacêutica
KR101990951B1 (ko) 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
CN106000294B (zh) * 2016-07-04 2019-04-30 三峡大学 一种高膨胀低收缩率膨润土及制备方法
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US4984807A (en) * 1990-01-12 1991-01-15 Baruch Shiryon Board game
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
DK0542926T3 (da) * 1990-08-07 1995-05-15 Pfizer Brug af grænsefladepolymeriserede membraner i frigivelsesanordninger
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
AU7706598A (en) * 1997-05-30 1998-12-30 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP0999830A1 (en) * 1997-07-01 2000-05-17 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
CN1406126A (zh) * 1998-10-01 2003-03-26 诺瓦提斯公司 新型缓释口服制剂
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system

Also Published As

Publication number Publication date
RU2281758C2 (ru) 2006-08-20
HUP0202744A3 (en) 2004-05-28
DE60037897D1 (de) 2008-03-13
SK286651B6 (sk) 2009-03-05
CN1376058A (zh) 2002-10-23
JP2003510268A (ja) 2003-03-18
IL148908A (en) 2010-06-16
IL148908A0 (en) 2002-09-12
WO2001022944A1 (en) 2001-04-05
NO20021452L (no) 2002-03-22
GB9923045D0 (en) 1999-12-01
CA2379595A1 (en) 2001-04-05
NZ517335A (en) 2003-10-31
CY1107923T1 (el) 2013-09-04
MY128759A (en) 2007-02-28
CZ301455B6 (cs) 2010-03-10
ES2299438T3 (es) 2008-06-01
NO20021452D0 (no) 2002-03-22
KR20050100710A (ko) 2005-10-19
US20060246101A1 (en) 2006-11-02
CZ20021028A3 (cs) 2002-06-12
AU769646B2 (en) 2004-01-29
SK4132002A3 (en) 2002-10-08
CO5210867A1 (es) 2002-10-30
DK1216032T3 (da) 2008-06-02
AR025792A1 (es) 2002-12-11
EP1216032A1 (en) 2002-06-26
KR20020038778A (ko) 2002-05-23
PE20010568A1 (es) 2001-05-29
EP1216032B1 (en) 2008-01-23
DE60037897T2 (de) 2008-12-24
ECSP003685A (es) 2002-05-23
HUP0202744A2 (hu) 2003-01-28
NO331480B1 (no) 2012-01-16
AU1019701A (en) 2001-04-30
PL354075A1 (en) 2003-12-15
PL200822B1 (pl) 2009-02-27
KR100661441B1 (ko) 2006-12-27
ZA200202369B (en) 2002-12-24
PT1216032E (pt) 2008-04-29
CN1213737C (zh) 2005-08-10
WO2001022944A8 (en) 2001-07-26
TR200200683T2 (tr) 2002-07-22
ATE384517T1 (de) 2008-02-15
US20110038897A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
BR9914251A (pt) Formulações orais de liberação sustentada
HRP20020088B1 (en) Levodopa/carbidopa/entacapone pharmaceutical preparation
BR0115965A (pt) Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
CA2238271A1 (en) Pharmaceutical compositions comprising flurbiprofen
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GEP20053473B (en) High Potency Dihydroergotamine Compositions
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
NO20001290D0 (no) Multiple-enhet sammensetninger av ikke-steroid anti- inflammatorisk medikament substans (NSAID) med modifisert frigjøring
AP1954A (en) Controlled release compositions comprising nimesulide.
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
AP2003002763A0 (en) Controlled release formulations for oral administration
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
BR0014440A (pt) Formulações de liberação controlada oral
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
PT991409E (pt) Composicoes farmaceuticas de libertacao controlada contendo tiagabina
ES2172172T3 (es) Composiciones farmaceuticas solidas para la administracion por via oral que permiten la liberacion modulada de nicorandil y su procedimiento de preparacion.
MY145885A (en) Controlled release formulations for oral administration
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
MD20040296A (ro) Compoziţie farmaceutică, conţinând oxcarbazepină cu eliberare prelungită a ingredientului activ
ECSP982396A (es) Composiciones que contienen tetrahidrolipstatina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.